What do systematic reviews say?

Ruxolitinib vs placebo

Ruxolitinib may leads to lower overall survival (number of deaths at compared with placebo (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  HR 0.51 [0.27, 0.98]
  1 study · 309 participants
  Low

Ruxolitinib vs best available therapy

Ruxolitinib showed no clear difference in overall survival (number of deaths at compared with best available therapy (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  HR 0.7 [0.2, 2.47]
  1 study · 219 participants
  Low

Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes overall survival (OS), measured by the number of deaths over time, compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.49 [0.15, 1.64]
  1 study · 150 participants
  Very low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 23 participants
  Moderate

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant targeted treatment (BRAF/MEK inhibition) changes overall survival (OS), measured by number of deaths over time,Median compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.28 [0.03, 2.25]
  1 study · 21 participants
  Very low

Neoadjuvant treatment vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant treatment changes overall survival (OS), measured by the number of deaths over time… compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.43 [0.15, 1.21]
  2 studies · 171 participants
  Very low